- £81.91bn
- £95.80bn
- £32.67bn
REG - GSK PLC - Statement: Zantac (ranitidine) litigation
AnnouncementREG - GSK PLC - Omjjara approved in Japan for myelofibrosis
AnnouncementREG - GSK PLC - EMA validates Jemperli marketing authorisation
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Statement: Zantac (ranitidine) litigation
AnnouncementREG - GSK PLC - Statement: Zantac (ranitidine) litigation
AnnouncementREG - GSK PLC - FDA approves Arexvy for adults 50-59 at risk
AnnouncementREG - Allianz Global Invs - Top 10 Holdings
AnnouncementREG - GSK Capital B.V. - Annual Financial Report
AnnouncementREG - GSK PLC - Total Voting Rights
AnnouncementREG - GSK PLC - Unprecedented results in Jemperli trial continue
AnnouncementREG - GSK PLC - ASCO positive Blenrep DREAMM-8 trial results
AnnouncementREG - GSK PLC - Statement: Zantac (ranitidine) litigation
AnnouncementREG - Crism Therapeutics - Admission to Trading and First Day of Dealings
AnnouncementREG - GSK PLC - Statement: Zantac (ranitidine) litigation
AnnouncementREG - GSK PLC - Positive phase III asthma results for depemokimab
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - GSK completes sale of shares in Haleon plc
Announcement